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Background/aim: This study aimed to investigate the correlation between the prevalence of problematic pathogens and the clinical
status of women with bacterial vaginosis (BV).
Materials and methods: Gardnerella vaginalis, Atopobium vaginae, and Mobiluncus spp. were detected using a multiplex PCR assay, and
their role in the infection of Bulgarian women with clinically heterogeneous BV was evaluated.
Results: The predominant BV-associated pathogen identified was G. vaginalis with an incidence of 98.39%, followed by A. vaginae
(68.05%) and Mobiluncus spp. at 17.01%. The coexistence of A. vaginae and G. vaginalis was more common in women with discharge
(in 72.04%) and in patients with chronic recurrent BV than among asymptomatic or newly diagnosed BV cases (P < 0.05). Mobiluncus
spp. was detected mostly in coinfections, in association with Trichomonas vaginalis. The coinfections were predominantly related to
recurrent BV and with complications (P < 0.05).
Conclusion: This is the first study about the correlation between problematic pathogens and clinically heterogeneous BV in Bulgarian
women. High frequency of infection with key BV-related pathogens was observed in childbearing women. The incidence was shown
to often correlate with coexistent T. vaginalis, with severity of infection, and with complicated and recurrent BV after unsuccessful
treatments. Screening should be considered in reproductive health programs.
Key words: Bacterial vaginosis, PCR, Gardnerella vaginalis, Atopobium vaginae, Mobiluncus spp.

1. Introduction
Bacterial vaginosis (BV) is a leading genital tract infection
in reproductive-age women. This very common vaginal
disorder occurs when beneficial Lactobacillus spp. become
replaced by various obligate or facultative anaerobic
bacteria, which are normally present in very low numbers
or are absent in healthy women (1,2). The abnormal flora
has been mostly defined by the presence of high Mobiluncus
spp. counts (more than 104 CFU/mL) visible on Gram
staining, with a Nugent score of 9 or 10 (3,4). When the
level of lactobacilli in the vaginal niche is 107–108 CFU/mL,
they have antimicrobial properties that inhibit the growth
and initial adhesion of Gardnerella vaginalis to epithelial
cells and its biofilm-forming ability due to production of
hydrogen peroxide, bacteriocins, and lactic acid, which
maintains low values (about 4.5) of pH (5,6). Bacteria such
as G. vaginalis, Atopobium vaginae, and Mobiluncus spp.
are recognized as predominant vaginal pathogens and as
sensitive indicators in the diagnosis of BV, although many
* Correspondence: rtgergova@gmail.com
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other BV-related pathogens have been found with variable
frequency (7–11). A. vaginae and Mobiluncus spp. are not
susceptible to metronidazole, which is a problem for the
successful treatment of infection, explaining their key role
in the development of chronic and recurrent BV (9,12).
Currently, the causes behind the replacement of normal
microbiota by nonbeneficial bacteria are still unknown.
When the size of the vaginal lactobacillus population
begins to decrease, it results in enhanced virulence of G.
vaginalis. Only G. vaginalis has been shown to exhibit a
strong ability to adhere to the vaginal epithelium; A. vaginae
and Mobiluncus spp. can also adhere, but to a lesser extent
(4,7,9). Other anaerobes detected in BV-positive women
have not shown any adherence, which is a significant
marker for their low virulence and their uncertain and
erratic participation in this infectious process (10,11).
Some epidemiological (13) and experimental data in
animal models and in studies with volunteers (14,15)
suggest that BV is a sexually transmitted disease, although
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some authors believe that the infection is polymicrobial
when there is coexistence of many anaerobes (16).
This transmission of infection is more typically caused
by a single microbial agent with secondary anaerobic
activation, i.e. the pathogenesis is similar to that of
Trichomonas vaginalis infection (17). G. vaginalis forms a
significantly thicker biofilm than other vaginal pathogens,
which is why it is a predominant species in all BV biofilms
(6,17,18). This bacterial species is strongly cytotoxic for
vaginal epithelial cells. These data suggest that G. vaginalis
has a higher virulence potential than other BV-related
species. The bioactive agents produced by this bacterium,
such as the exotoxin vaginolysin and the hydrolytic
enzymes sialidase and prolidase, cause the degradation
of mucin and epithelium (9,18,19). The key presence of
metronidazole-resistant A. vaginae and Mobiluncus spp.
only at high Nugent scores implicates them as associated
with the clinical development of BV (7–9).
The aim of this study was to determine the most
problematic and key causative agents of BV using
polymerase chain reaction (PCR) and to evaluate the
correlation between their prevalence and the clinical status
of Bulgarian patients.
2. Materials and methods
2.1. Patients and collection of specimens
Vaginal samples from 538 women from Bulgaria aged
16–45 years were collected between September 2013 and
December 2014 and stored at –20 °C for up to 2 days
before extraction of total bacterial DNA. Specimens
collected from enrolled subjects consisted of 2 vaginal
swabs followed by a vaginal lavage. One of the swabs was
rolled onto a glass slide, air-dried, and then Gram-stained
for microscopic assessment of BV using the Nugent criteria
(0–3: normal vaginal flora [NVF]; 4–6: intermediate;
7–10: BV) (3,8). Vaginal lavage was collected by washing
the vaginal vault for 30–40 s using a syringe and 5 mL of
nonpyrogenic sterile saline. Then 0.5 mL of the sample was
placed in a sterile vial and frozen at –70 °C until later use for
DNA extraction. The samples were analyzed by molecular
genetic methods to determine some key causative agents
of vaginal disorder. The inclusion criteria for the examined
people enrolled in this study were: sexually active women
of reproductive age; no antimicrobial therapy received
in the week before the study; negative serological results
for Chlamydia trachomatis; positive microscopic smears
with BV according to the Nugent score (3) for all groups
excluding the control group (n = 103) with microscopic
diagnosis of NVF (ecosystem with only lactobacilli and
visible absence of other bacterial morphotypes). The
patients with microscopically detected BV were divided
into the following groups based on their clinical status:
A and B, asymptomatic (n = 152) and symptomatic with

symptoms of discharge (n = 279), respectively; C/D,
pregnant (n = 188)/nonpregnant (n = 247); E, women with
no complications and no relapse of new-found BV (n =
130); F, people with recurrent symptoms and a tendency to
develop chronic BV without coinfection with Trichomonas
vaginalis (TV) (n = 170); G, recurrent BV with coinfection
with TV (n = 78); H, patients with complications of BV
such as imminent abortion and premature birth (n =
57). The exclusion criteria were the presence of tumors,
amenorrhea, HIV infection, hepatitis B or C, syphilis,
gonorrhea, and candidosis.
Informed consent forms were obtained from all
participants and were included in their standard medical
records. There was no personal patient information in the
database. The hospital’s ethics committee granted study
approval.
2.2. Gram staining and culture method
These methods were performed as previously described (8).
2.3. DNA isolation
Total DNA from vaginal samples was isolated using the
DNAsorb-AM nucleic acid extraction kit (AmpliSens)
according to the manufacturer’s guidelines. DNA isolated
in parallel from G. vaginalis ATCC 14018 (American Type
Culture Collection) was used as a positive control.
2.4. Polymerase chain reaction (PCR) assay
A multiplex PCR assay for detection of the major BV
causative agents, such as G. vaginalis, A. vaginae, and
Mobiluncus spp., targeting their 16S ribosomal ribonucleic
acid (rRNA) genes was performed. All Mobiluncus spp.positive samples were additionally examined by a speciesspecific PCR test for the identification of M. curtisii.
The oligonucleotides used as primers for amplification
(4,20,21) were synthesized by Alpha DNA (Canada).
They were verified for specificity using the Basic Local
Alignment Search Tool (BLAST) program available from
the NCBI (http//:www.nbi.nlm.nih.gov/BLAST).
PCR was carried out with 10 ng of template DNA,
0.25 µM of each primer, 0.2 mM deoxyribonucleoside
triphosphates, 1X reaction buffer, 2 mM MgCl2, and 0.5 U
Prime Taq DNA polymerase (Genet Bio) in a total volume
of 25 µL. The DNA was amplified using the following
protocol: initial denaturation (95 °C for 5 min), followed
by 30 cycles of denaturation (95 °C for 45 s), annealing
(58 °C and 69 °C for 45 s), and extension (72 °C for 45
s), with a single final extension of 7 min at 72 °C. PCR
products were separated in 1% agarose gel for 50 min at
140 V, stained with ethidium bromide (0.5 µg/mL), and
detected by UV transillumination (wavelength: 312 nm).
The amplification products were identified on the basis of
fragment length (4,20,21).
Detection of Trichomonas vaginalis (TV) in vaginal
samples was done as previously described by Madico et al.
(22).
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2.5. Statistical analysis
The data were analyzed using the chi-square test and
Fisher’s exact test for categorical variables. All analytical
procedures were performed using SPSS 16.0 for Windows
(SPSS Inc., Chicago, IL, USA). Differences were considered
statistically significant at P < 0.05.
3. Results
Representative multiplex PCR amplicons of BV-associated
pathogens are presented in the Figure. The distribution
of BV causative agents detected in women with
microscopically diagnosed BV and in healthy women with
microscopic evaluation of NVF is summarized in Table 1. In
women with NVF the incidence of G. vaginalis was 5.83%;
A. vaginae was present in only 0.97%, and no Mobiluncus
spp. were detected. The most common bacterial pathogen
identified, alone or in microbial combinations (Tables 1
and 2), in all patients with microscopic smears with BV
was G. vaginalis, with an incidence of 98.39%, followed
by A. vaginae (68.05%), and Mobiluncus spp. at 17.01%,
particularly M. curtisii (9.20%). In symptomatic women,
the prevalence of both A. vaginae and G. vaginalis was very
high (72.04%; P < 0.05), more than 2 times higher than
in asymptomatic ones. Triple infection with G. vaginalis,
A. vaginae, and Mobiluncus spp. was observed in 15.19%
of the patients with discharge (P < 0.05), amounting to
a total of 87.23% of cases of multiple (double or triple)
infection, as shown in Table 2. About one-fourth of BVpositive samples contained G. vaginalis alone; only 1.4%
contained A. vaginae and 0.23% M. curtisii alone. In the

other samples, coinfections were demonstrated (Table
2). In the prevailing cases with chronic recurrent BV,
presented in Table 3, the PCR results were positive for the
2 leading etiological agents, G. vaginalis and A. vaginae (P
< 0.05). The rarer Mobiluncus spp. pathogens were also
identified in symptomatic patients, but there was high
association with more complications such as coinfection
with T. vaginalis (P < 0.05) (Table 3). Coinfections with A.
vaginae and Mobiluncus spp. together only and lack of G.
vaginalis were not observed, as shown in Tables 2 and 3.
4. Discussion
A significant difference (P < 0.05) among women with
microscopic diagnosis of BV and NVF was demonstrated in
Table 2. The most prevalent etiological agent, G. vaginalis,
was present in all tested groups of patients with BV and
was rarely found in the healthy population (Tables 1–3),
which is in agreement with the concept of the leading and
initial role of G. vaginalis in BV pathogenesis (1,15). New
experimental data for significant divergence of 2 different
genotypes, biotypes, and the virulence of G. vaginalis
isolated from healthy and ill persons have been reported
in recent years (5,19,20,23). The commensal strains of G.
vaginalis demonstrate reduced biofilm-forming capacity
and cytotoxicity, unlike the pathogenic isolates, which
exhibit higher adhesive and aggregative potential (24,25).
We determined that the combination mostly detected
(more than 72%) in Bulgarian patients, especially in
ones with vaginal discharge, was that of the 2 major
pathogens, G. vaginalis and A. vaginae, and it was

Figure. Multiplex PCR (agarose gel electrophoresis) for detection of G. vaginalis (331
bp), A. vaginae (155 bp), and Mobiluncus spp. (422 bp). Lane 1: DNA marker GeneRule
100 bp Plus DNA Ladder (Fermentas). Lanes 2, 3, 5, and 7 represent the positive clinical
samples for G. vaginalis and A. vaginae; lanes 4 and 6, positive samples for G. vaginalis,
A. vaginae, and Mobiluncus spp.; lane 7: G. vaginalis-positive sample; lane 9: a negative
sample.
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Table 1. Prevalence of key vaginal pathogens in women according to microscopic evaluation of BV*.
P-value
between women with
BV and NVF

Patients
BV-associated pathogens

With microscopic
diagnosis “BV”
N = 435 n (%)

With microscopic
diagnosis “NVF”**
N = 103 n (%)

G. vaginalis (Gv)

428 (98.39)

6 (5.83)

<0.00001

A. vaginae (Av)

296 (68.05)

1 (0.97)

<0.00001

Mobiluncus spp. (Msp)

74 (17.01)

0

<0.00001

* Bacterial vaginosis.
** Normal vaginal flora.

Table 2. Distribution of BV-associated pathogens among 435 symptomatic and
asymptomatic women (2A) and respectively in pregnant and nonpregnant ones
(2B).
BV-related pathogens

Group A*

Group B*

P-value*

G. vaginalis (Gv)

99

17

<0.00001

A. vaginae (Av)

2

4

0.612013

1

0.570438

44

195

<0.00001

4

0.256975

11

0.162942

M. curtisii (Mc)
Gv & Av
Gv & Mc
Gv & Msp

7

Gv & Av & Mc

35

0.000905

Gv & Av & Msp

16

0.023971

Total

152

279

BV-related pathogens

Group C*

Group D*

P-value*

G. vaginalis (Gv)

60

56

0.101815

A. vaginae (Av)

3

3

0.739168

M. curtisii (Mc)

1

Gv & Av

101

138

0.809819

Gv & Mc

1

3

0.463855

Gv & Msp

4

14

0.077322

0.252416

Gv & Av & Mc

13

22

0.484592

Gv & Av & Msp

5

11

0.341983

Total

188

247

*Group A: Asymptomatic women; Group B: Symptomatic.
*Group C: Pregnant women; Group D: Nonpregnant.
*P-values are a comparison between women with Groups A and B and with C
and D.
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Table 3. Distribution of BV-associated pathogens in 435 women with different clinical status.
P-value*
comparison
between E and F

P-value*
comparison
between E and G

P-value*
comparison
between E and H

5

0.000027

<0.00001

<0.00001

1

0.881397

0.8823

<0.00001

BV-related
pathogens

Group E*

Group F*

Group G*

G. vaginalis (Gv)

74

37

A. vaginae (Av)

2

3

M. curtisii (Mc)

Group H*

1

Gv & Av

46

119

Gv & Mc

1

3

Gv & Msp

3

Gv & Av & Mc

0.382464
37

37

<0.00001

0.00101

0.264777

0.782398

0.462007

0.439234

0.372418

4

9

2

0.979948

0.009785

0.564982

2

18

15

0.217362

<0.00001

<0.00001

0.101341

0.044078

0.489855

Gv & Av & Msp

4

1

8

3

Total

130

170

78

57

*Group E: Patients with no complications and no relapse of BV.
*Group F: Patients with recurrent BV without coinfection with TV.
*Group G: Recurrent and complicated BV with coinfection with TV
*Group H: Patients with complications of BV such as abortus imminens and premature birth.
*P-values are a comparison between women in Group E and F; E and G; and E and H.

lacking in samples with NVF. A. vaginae was identified
in 89.61% of symptomatic cases, whereas its incidence in
the asymptomatic women was 30.26% and in the healthy
women, 0.97%; its incidence was therefore 3 times higher
than in asymptomatic women and more than 90 times
higher than in women with NVF. Interestingly, there were
large differences between the prevalence of A. vaginae
in the studied groups (P < 0.05). Other recent studies in
Europe report G. vaginalis and A. vaginae in 96% and
87% of clinically prominent BV cases, respectively (26).
Bradshaw et al. observed that 82% of Australian women
with recurrent BV had both G. vaginalis and A. vaginae,
while fewer had G. vaginalis alone (27). Ling et al. detected
A. vaginae in 84% of Chinese women with symptomatic
BV (28). In our study, both pathogens, G. vaginalis and
A. vaginae, were found in about 70% of the clinically
expressed BV cases and among the patients with chronic
recurrent BV. A. vaginae has frequently been detected in
symptomatic BV-positive cases, most likely because most
strains of this microbial agent produce peptidyl peptidase
and form ammonia, a substance very favorable for the
growth of G. vaginalis, which contributes to the smell and
irritation associated with vaginal discharge (29). Difficultto-treat multiple-pathogen infections with A. vaginae
and Mobiluncus spp. in a double or triple combination
with G. vaginalis were detected in more than 86% of
the patients with recurrent and symptomatic BV. These
results support the idea of a leading role of both of these
BV-associated pathogens, which are considered by many
authors as essential markers of this infection (1,18,27).
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The coinfections were predominantly related to recurrent
BV and some complications such as abortus imminens
and preterm birth (P < 0.05). Other authors have found
persistence of both Mobiluncus spp. and M. curtisii in
more than 60% of BV-positive women after treatment with
metronidazole (4). Our results showed that G. vaginalis
alone was detected in 6.5% of the complicated cases and in
nearly 57% of the uncomplicated cases. The bacterial loads
of G. vaginalis and A. vaginae infections were higher when
the 2 species were present together in vaginal samples
than in cases when biofilm was formed by G. vaginalis
alone. A. vaginae has been reported as part of the vaginal
ecosystem together with G. vaginalis, but not alone (10).
The high load of this synergistic bacterial combination
causes a more severe infection and poses a significant risk
of preterm birth (7,30).
A combination of BV with TV coinfection was found
in 17.93% of the examined patients, which was more than
the incidence of 13.69% reported in a previous Bulgarian
study (8). In most of these samples, all 3 pathogens (G.
vaginalis, A. vaginae, and Mobiluncus spp.) were detected,
which suggests heavier anaerobic infection. A synergistic
effect between protozoa and these anaerobic bacteria
was demonstrated. There are data that Mobiluncus
spp. have never been isolated in pure cultures, but
only in mixed cultures with other anaerobes in vaginal
samples predominantly from patients with BV or pelvic
inflammatory disease, or from amniotic fluid; however, the
data’s clinical significance is as of yet unclear (4,9,29). An
investigation in rhesus macaques revealed that most of the
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tested animals carried such microorganisms, especially
M. curtisii, in their vaginal ecosystem, which were
harbored together with Gardnerella-like bacteria (9,30).
The adherence of Mobiluncus spp. by polar attachment
via exopolysaccharides of the glycocalyx is increased
when the pH increases, e.g., at pH 7.5. After adhesion,
the growth of anaerobic organisms appears in the biofilm
(9). Mobiluncus species have varying sensitivity to
metronidazole. M. curtisii shows a high level of resistance,
which is why it is more difficult to eradicate (9,28,29).
The prevalence of antimicrobial-resistant Mobiluncus spp.
isolated from specimens collected from Turkish women
is reported to have become over 80% in recent years (31).
The nonsusceptibility of A. vaginae to metronidazole,
the antibiotic commonly used for treatment of BV, is
another problem that reinforces the trends for persistence
of vaginal infections (27,29). Some recent data about G.
vaginalis strains with intrinsic metronidazole resistance
show other variants of recurrent BV after frontline
therapy (32). Such strains are found in 80%–90% of
cases of relapse after treatment with this drug (32). In
some cases, 12 months after therapy with metronidazole,
A. vaginae and G. vaginalis may still persist in vaginal
samples (27). Treatment with clindamycin reduces
the resident microflora, such as lactobacilli, that are
resistant to metronidazole (>256 µg/mL) but susceptible
to clindamycin (0.023–0.125 g/mL). Only nifuratel and
rifaximin have shown strong in vitro activity against the
resistant and problematic etiological agents A. vaginae,
G. vaginalis, and Mobiluncus spp. without nonbeneficial
effects on lactobacilli (12,33,34). New studies have
presented data that demonstrate that the known antibiotic
therapy alone is not a viable option for the eradication of

the BV-related bacteria in biofilm; rather, combinations
of antimicrobial drugs, disinfectants, and probiotics are
more useful (18,35–38).
To our knowledge, this is the first study that focuses
on the correlation between problematic BV-associated
pathogens and the clinical status of women with BV in
Bulgaria. The predominant etiological agent detected
using multiplex PCR in all tested groups was G. vaginalis.
High frequency of the key combination of G. vaginalis
and A. vaginae was detected in Bulgarian women, more
frequently in symptomatic patients than in asymptomatic
ones. Taken together, the results from our study indicate
an alarmingly high prevalence of causative agents of BV
that are problematic for therapy, such as A. vaginae and
Mobiluncus spp. with G. vaginalis, and also T. vaginalis,
in women of childbearing age in Bulgaria. The prevalence
of coinfection with 2 or 3 agents in the group of patients
with recurrent BV is an acknowledgment of the virulence
and the leading role of these agents in the etiology and
pathogenesis of BV. Some of the identified pathogens had
intrinsic metronidazole resistance. This study supports
the idea that screening for such pathogens should be a
very useful strategy in the choice of effective therapy as
well as in the prevention of relapses and complications
of BV, and should be considered in reproductive health
programs. Development and evaluation of new methods,
new disinfection strategies, and new ways of treatment,
especially for recurrent BV infections, are needed.
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